Recent Analysts’ Ratings Changes for Thermo Fisher Scientific (TMO)

A number of firms have modified their ratings and price targets on shares of Thermo Fisher Scientific (NYSE: TMO) recently:

• 8/5/2026 – Thermo Fisher Scientific was given a new $650.00 price target by Stifel Nicolaus.
• 8/1/2026 – Thermo Fisher Scientific was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/27/2026 – Thermo Fisher Scientific had its price target raised by Piper Sandler from $510.00 to $600.00. They now have a “neutral” rating on the stock.
• 7/24/2026 – Thermo Fisher Scientific had its price target raised by Morgan Stanley from $620.00 to $650.00. They now have an “overweight” rating on the stock.
• 7/24/2026 – Thermo Fisher Scientific had its price target raised by Royal Bank Of Canada from $490.00 to $580.00. They now have a “sector perform” rating on the stock.
• 7/24/2026 – Thermo Fisher Scientific had its price target raised by Barclays PLC from $625.00 to $650.00. They now have an “overweight” rating on the stock.
• 7/23/2026 – Thermo Fisher Scientific had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $630.00 price target on the stock.
• 7/14/2026 – Thermo Fisher Scientific was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 7/6/2026 – Thermo Fisher Scientific was given a new $570.00 price target by Evercore Inc.
• 6/29/2026 – Thermo Fisher Scientific was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 6/26/2026 – Thermo Fisher Scientific is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $520.00 price target on the stock.
• 6/25/2026 – Thermo Fisher Scientific was upgraded by Sanford C. Bernstein to “hold”.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 26,553 shares of company stock worth $15,343,589 over the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.